Oral premalignant lesions of smokers and non-smokers show similar carcinogenic pathways and outcomes. A clinicopathological and molecular comparative analysis.
HPV
head and neck cancer
microarray
oral cancer
oral premalignant disorder
Journal
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
ISSN: 1600-0714
Titre abrégé: J Oral Pathol Med
Pays: Denmark
ID NLM: 8911934
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
revised:
04
04
2019
received:
22
02
2019
accepted:
15
04
2019
pubmed:
22
4
2019
medline:
20
3
2021
entrez:
22
4
2019
Statut:
ppublish
Résumé
Oral premalignant lesions (OPML) are frequently extensive and multifocal leading high morbidity for patients. Although oral squamous carcinoma (OSCC) in non-smoker patients is increasing, little is known about OPML and the carcinogenesis process in these patients. The aims of the study were to insight and compare the clinicopathological and molecular characteristics of OPML of non-smoker and smoker patients from which one or multiple OSCC have developed. Eighty-one patients showing extensive and/or multifocal OPML were included in the survey. HPV and EBV were investigated by PCR and in situ hybridization respectively. Cytogenetic studies were performed by microarray in sequential progressive 30 lesions; p53 expression was investigated by immunohistochemistry. The patients were 41 males and 40 females, ages ranging from 32 to 93 years (median 64); 43 (53%) were smokers. Non-smokers were more frequently female with a median age of 68, whereas smokers were men with a median age of 60 (P = 0.005). HPV and EBV were negative in all cases. The most consistent and earliest cytogenetic alterations in both non-smokers and smokers were loss of heterozygosity (LOH) and losses of locus harboring tumor suppressor genes. Progression to high-grade dysplasia and OSCC showed progressive addition of LOH, tumor suppressor losses, and oncogenic gains. Non-smoker patients are mostly elderly female and show oral carcinogenic pathways and outcomes similar to smoker patients.
Sections du résumé
BACKGROUND
BACKGROUND
Oral premalignant lesions (OPML) are frequently extensive and multifocal leading high morbidity for patients. Although oral squamous carcinoma (OSCC) in non-smoker patients is increasing, little is known about OPML and the carcinogenesis process in these patients. The aims of the study were to insight and compare the clinicopathological and molecular characteristics of OPML of non-smoker and smoker patients from which one or multiple OSCC have developed.
METHODS
METHODS
Eighty-one patients showing extensive and/or multifocal OPML were included in the survey. HPV and EBV were investigated by PCR and in situ hybridization respectively. Cytogenetic studies were performed by microarray in sequential progressive 30 lesions; p53 expression was investigated by immunohistochemistry.
RESULTS
RESULTS
The patients were 41 males and 40 females, ages ranging from 32 to 93 years (median 64); 43 (53%) were smokers. Non-smokers were more frequently female with a median age of 68, whereas smokers were men with a median age of 60 (P = 0.005). HPV and EBV were negative in all cases. The most consistent and earliest cytogenetic alterations in both non-smokers and smokers were loss of heterozygosity (LOH) and losses of locus harboring tumor suppressor genes. Progression to high-grade dysplasia and OSCC showed progressive addition of LOH, tumor suppressor losses, and oncogenic gains.
CONCLUSION
CONCLUSIONS
Non-smoker patients are mostly elderly female and show oral carcinogenic pathways and outcomes similar to smoker patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
280-286Subventions
Organisme : Instituto de Salud Carlos III (ICSiii)-Fondos de Investigacion Sanitaria and ERDF "one way to Europe"
ID : PI11/01570
Organisme : Fundacion Mutua Madrileña
ID : AP94722011
Organisme : Premio Emili Letang of the Hospital Clinic of Barcelona
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.
Braakhuis B, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization evidence and clinical implications. Cancer Res. 2003;63(8):1727-1730.
Castellsagué X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108(6):djv403.
Gupta B, Johnson NW. Systematic review and meta-analysis of association of smokeless tobacco and of betel quid without tobacco with incidence of oral cancer in South Asia and the Pacific. PLoS One. 2014;9(11):e113385.
Woo S-B, Cashman EC, Lerman MA. Human papillomavirus-associated oral intraepithelial neoplasia. Mod Pathol. 2013;26(10):1288-1297.
Hutt-Fletcher LM. The long and complicated relationship between Epstein-Barr virus and epithelial cells. J Virol. 2017;91(1):e01677-16.
Gillenwater AM, Vigneswaran N, Fatani H, Saintigny P, El-Naggar AK. Proliferative verrucous leukoplakia: recognition and differentiation from conventional leukoplakia and mimics. Head Neck. 2014;36(11):1662-1668.
Gonzalez-Moles MA, Gil-Montoya JA, Ruiz-Avila I, Bravo M. Is oral cancer incidence among patients with oral lichen planus/oral lichenoid lesions underestimated? J Oral Pathol Med. 2017;46(2):148-153.
8th Edition of the UICC TNM classification of Malignant Tumors published | UICC. https://www.uicc.org/8th-edition-uicc-tnm-classification-malignant-tumors-published. Accessed November 15, 2018.
El-Naggar AK, Chan J, Rubin Grandis J, Takata T, Slootweg PJ,International Agency for Research on Cancer. WHO Classification of Head and Neck Tumours. http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Head-And-Neck-Tumours-2017. Accessed October 25, 2018.
van Houten V, Tabor MP, van den Brekel M, et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol. 2002;198(4):476-486.
Califano J, Westra WH, Meininger G, Corio R, Koch WM, Sidransky D. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res. 2000;6(2):347-352.
Graveland AP, Golusinski PJ, Buijze M, et al. Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. Int J cancer. 2011;128(8):1852-1859.
Zhang L, Poh CF, Williams M, et al. Loss of heterozygosity (LOH) profiles - validated risk predictors for progression to oral cancer. Cancer Prev Res. 2012;5(9):1081-1089.
Rock LD, Rosin MP, Zhang L, Chan B, Shariati B, Laronde DM. Characterization of epithelial oral dysplasia in non-smokers: First steps towards precision medicine. Oral Oncol. 2018;78:119-125.
Ambatipudi S, Gerstung M, Pandey M, et al. Genome-wide expression and copy number analysis identifies driver genes in gingivobuccal cancers. Genes Chromosom Cancer. 2012;51(2):161-173.
Cervigne NK, Machado J, Goswami RS, et al. Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis? Hum Mol Genet. 2014;23(10):2618-2628.
Bhosale PG, Cristea S, Ambatipudi S, et al. Chromosomal alterations and gene expression changes associated with the progression of leukoplakia to advanced Gingivobuccal cancer. Transl Oncol. 2017;10(3):396-409.
Dos Santos Costa SF, Brennan PA, Gomez RS, et al. Molecular basis of oral squamous cell carcinoma in young patients: Is it any different from older patients? J Oral Pathol Med. 2018;47(6):541-546.
Alos L, Moyano S, Nadal A, et al. Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer. 2009;115(12):2701-2709.
Bondy SJ, Victor JC, Diemert LM. Origin and use of the 100 cigarette criterion in tobacco surveys. Tob Control. 2009;18(4):317-323.
Lee DJ, Schönleben F, Banuchi VE, et al. Multiple tumor-suppressor genes on chromosome 3p contribute to head and neck squamous cell carcinoma tumorigenesis. Cancer Biol Ther. 2010;10(7):689-693.
Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046):1154-1157.
Lawrence MS, Sougnez C, Lichtenstein L, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576-582.
Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157-1160.
van den Broek GB, Wreesmann VB, van den Brekel M, Rasch C, Balm A, Rao PH. Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13(15 Pt 1):4386-4391.
Vincent-Chong VK, Salahshourifar I, Woo KM, et al. Genome wide profiling in oral squamous cell carcinoma identifies a four genetic marker signature of prognostic significance. PLoS One. 2017;12(4):e0174865.
Belobrov S, Cornall AM, Young RJ, et al. The role of human papillomavirus in p16-positive oral cancers. J Oral Pathol Med. 2018;47(1):18-24.
Alos L, Hakim S, Larque A-B, et al. p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas. Virchows Arch. 2016;469(3):277-284.
Koo K, Barrowman R, McCullough M, Iseli T, Wiesenfeld D. Non-smoking non-drinking elderly females: a clinically distinct subgroup of oral squamous cell carcinoma patients. Int J Oral Maxillofac Surg. 2013;42(8):929-933.